Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

Mirabegron confirmed safe and effective for overactive bladder syndrome

12 Jan 2020

Mirabegron may be used to effectively treat overactive bladder (OAB) syndrome without presenting new and pressing safety concerns, a recent study has found.

Pooling from 10 phase 2–4 double-blind, 12-week mirabegron trials, researchers reassessed the efficacy and safety of the drug against OAB syndrome. Safety was evaluated through the occurrence of treatment-emergent adverse events (TEAEs), while bladder diary data were used for the assessment of treatment efficacy.

Both the 25-mg and 50-mg doses of mirabegron significantly improved OAB symptoms relative to placebo. For instance, the mean number of 24-hour incontinence episodes dropped from 2.95±0.10 and 2.51±0.05 at baseline to 1.35±0.08 and 1.10±0.05 at end-of-treatment for either dose, respectively. The change observed with placebo, in comparison, was statistically smaller.

A similar effect was reported for the number of micturitions per 24 hours. Mirabegron 25 and 50 mg induced a decrease of 2.05±0.08 and 2.12±0.04 episodes from baseline to end-of-treatment, respectively, both significantly greater than the placebo treatment’s net change of –1.55±0.05. The same was true for urgency and nocturia episodes per 24 hours.

The mean voided volume was significantly increased after treatment with 25-mg (change, 15.94±1.37) and 50-mg (change, 23.17±0.84) mirabegron, likewise statistically outperforming placebo.

These improvements did not come with new safety signals. TEAEs included dry mouth, constipation, urinary tract infection, tachycardia and treatment-emergent hypertension. However, these occurred more commonly in patients treated with antimuscarinics vs mirabegron. Placebo treatments showed the lowest incidence of TEAEs.

Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.